Oncology Drug updates & Clinical Pearls for Toxicity Management
To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.
Starts On:
3/24/2020: 12:00 AM
Ends On:
6/30/2020: 12:00 AM
Session Type:
Internet Activity Enduring Material
Credits:
0.75
Description:
Clinical Oncology Pharmacist
Manager, Clinical Pharmacy Services Washington University / Siteman cancer center
Financial Relationship: Nothing to disclose
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Advances in Oncology and Hematology, October 11-12, 2019, which was supported in part by Taiho Oncology, Celgene, and Novartis Pharmaceuticals.
Clinical Oncology Pharmacist
Financial Relationship: Nothing to disclose
Hailey E Hunter, NP
Nurse Practitioner
Financial Relationship: Nothing to disclose
Krystal F. Prater, RN, BSN, Nurse Coordinator
Financial Relationship: Nothing to disclose
Peter Westervelt, MD, PhD
Professor of Medicine; Co-Chair Director, Bone Marrow Transplantation
Financial Relationships
Research Support/Grants: Astellas Pharma Inc, Incyte Corp, Novartis Pharmaceuticals Corporation
Saiama Waqar, MBBS, MSCI
Associate Professor of Medicine; Co-Chair Director, Hematology and Oncology Fellowship Program
Financial Relationship: Nothing to disclose
Janelle Mann, PharmD, BCOP
Clinical Oncology Pharmacist
Financial Relationship: Nothing to disclose
Holly S. Comer, NP, ANP-BC
Adult Nurse Practitioner
Financial Relationship
Speakers Bureau/Honoraria: Seattle Genetics
Ramaswamy Govindan, MD
Professor of Medicine; Co-Chair Director, Section of Medical Oncology
Financial Relationships
Consulting/Advisory Committees: Achilles, Amgen
Faculty
Janelle Mann, PharmD, BCOPClinical Oncology Pharmacist
Manager, Clinical Pharmacy Services Washington University / Siteman cancer center
Financial Relationship: Nothing to disclose
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Advances in Oncology and Hematology, October 11-12, 2019, which was supported in part by Taiho Oncology, Celgene, and Novartis Pharmaceuticals.
Planning Committee
Lindsay Hladnik, PharmD, BCOPClinical Oncology Pharmacist
Financial Relationship: Nothing to disclose
Hailey E Hunter, NP
Nurse Practitioner
Financial Relationship: Nothing to disclose
Krystal F. Prater, RN, BSN, Nurse Coordinator
Financial Relationship: Nothing to disclose
Peter Westervelt, MD, PhD
Professor of Medicine; Co-Chair Director, Bone Marrow Transplantation
Financial Relationships
Research Support/Grants: Astellas Pharma Inc, Incyte Corp, Novartis Pharmaceuticals Corporation
Saiama Waqar, MBBS, MSCI
Associate Professor of Medicine; Co-Chair Director, Hematology and Oncology Fellowship Program
Financial Relationship: Nothing to disclose
Janelle Mann, PharmD, BCOP
Clinical Oncology Pharmacist
Financial Relationship: Nothing to disclose
Holly S. Comer, NP, ANP-BC
Adult Nurse Practitioner
Financial Relationship
Speakers Bureau/Honoraria: Seattle Genetics
Ramaswamy Govindan, MD
Professor of Medicine; Co-Chair Director, Section of Medical Oncology
Financial Relationships
Consulting/Advisory Committees: Achilles, Amgen
Objectives:
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Describe select new drug therapies approved in oncology during the past year
- Evaluate pharmacokinetics of newly approved therapies and its impact on concomitant medications
- Determine appropriate adverse effect monitoring, treatment of events and patient education for newly approved oncology therapies
Additional Information:
Target Audience: This course is designed for medical oncologists, hematologists, radiation oncologists, internists, hospitalists, general and family practice physicians, nurses, pharmacists and other health professionals who care for cancer patients.
Publication Date: March 24, 2020
Expiration Date: June 30, 2020
Target Audience: This course is designed for medical oncologists, hematologists, radiation oncologists, internists, hospitalists, general and family practice physicians, nurses, pharmacists and other health professionals who care for cancer patients.
Publication Date: March 24, 2020
Expiration Date: June 30, 2020
Accreditation Information:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 ANCC contact hours.
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 ANCC contact hours.
References:
- Siefker-Radtke AO, et al. J Clin Oncol.2018;36(suppl 15):4503.
- BalversaTM Horsham, PA: Janssen Products, LP; 2019.
- Piqray® East Hanover, NJ: Novartis Pharmaceuticals Corporation;2019.
- Andre F, et al. N Engl J Med. 2019;380:1929-1940.
Disclosure Information:
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
